Morgan Stanley: Assigns Pharmaron Beijing (03759) an "Overweight" rating, target price raised to HKD 35.6.

Morgan Stanley released a research report stating that after the announcement of Pharmaron Beijing's (03759) performance for the first half of 2026, it has raised its forecasts for 2026-2030 by 1-6% to reflect higher revenue assumptions, updated guidance from management, and improved operational efficiency. The target price has been increased from HK$31 to HK$35.6, with a rating of "Overweight."